Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganaplacide + lumefantrine + cipargamin
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ganaplacide + lumefantrine + cipargamin is an investigational non-artemisinin triple combination therapy being developed by Novartis, in collaboration with the Medicines for Malaria Venture (MMV), for the treatment of uncomplicated *Plasmodium falciparum* malaria. The combination consists of KLU156 (a fixed-dose combination of the novel imidazolopiperazine ganaplacide and a solid dispersion formulation of lumefantrine) and cipargamin (KAE609), a novel spiroindolone. This triple combination is designed to achieve a single-dose cure by combining fast parasite clearance, transmission-blocking activity, and a high barrier to resistance. Ganaplacide is believed to disrupt the parasite's internal protein secretory/trafficking pathway, lumefantrine inhibits the polymerization of toxic heme into non-toxic hemozoin, and cipargamin inhibits PfATP4, an essential sodium efflux pump of the malaria parasite.
- Other names
- KAF156 + lumefantrine + KAE609KAF156 + lumefantrine + cipargaminKLU156 + KAE609KLU156 + cipargaminganaplacide + lumefantrine + cipargaminganaplacide-lumefantrine + cipargaminganaplacide/lumefantrine + cipargamin
02
Targets
PfATP4 (Plasmodium falciparum ATPase 4)
Beyond the preview
Go deeper on ganaplacide + lumefantrine + cipargamin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganaplacide + lumefantrine + cipargamin.